Evolus Inc.

8.95-0.7400-7.64%Vol 1.03M1Y Perf -15.89%
Aug 9th, 2022 16:00 DELAYED
BID8.50 ASK9.11
Open9.65 Previous Close9.69
Pre-Market- After-Market9.05
 - -  0.10 1.12%
Target Price
16.57 
Analyst Rating
Strong Buy 1.43
Potential %
85.14 
Finscreener Ranking
★+     43.69
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     38.90
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
+     33.05
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
41.91 
Earnings Rating
Strong Buy
Market Cap502.04M 
Earnings Date
2nd Aug 2022
Alpha0.05 Standard Deviation0.46
Beta2.03 

Today's Price Range

8.919.77

52W Range

5.0614.34

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-10.28%
1 Month
-27.25%
3 Months
-5.19%
6 Months
7.07%
1 Year
-15.89%
3 Years
-46.05%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EOLS8.95-0.7400-7.64
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
57.30
-55.90
-51.60
-
-57.26
RevenueValueIndustryS&P 500US Markets
95.24M
1.70
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.28-0.42-50.00
Q01 2022-0.46-0.3132.61
Q04 2021-0.41-0.3319.51
Q03 2021-0.38-0.357.89
Q02 2021-0.30-0.31-3.33
Q01 2021-0.580.16127.59
Q04 2020-0.33-0.81-145.45
Q03 2020-0.50-0.3432.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2812.50Positive
9/2022 QR-0.2917.14Positive
12/2022 FY-1.0715.75Positive
12/2023 FY-0.3053.13Positive
Next Report Date-
Estimated EPS Next Report-0.28
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.03M
Shares Outstanding56.09K
Shares Float40.56M
Trades Count10.27K
Dollar Volume9.49M
Avg. Volume754.75K
Avg. Weekly Volume1.09M
Avg. Monthly Volume596.42K
Avg. Quarterly Volume574.94K

Evolus Inc. (NASDAQ: EOLS) stock closed at 9.69 per share at the end of the most recent trading day (a 3.09% change compared to the prior day closing price) with a volume of 650.57K shares and market capitalization of 502.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.

The one-year performance of Evolus Inc. stock is -15.89%, while year-to-date (YTD) performance is 48.85%. EOLS stock has a five-year performance of %. Its 52-week range is between 5.061 and 14.34, which gives EOLS stock a 52-week price range ratio of 41.91%

Evolus Inc. currently has a PE ratio of -9.80, a price-to-book (PB) ratio of 10.68, a price-to-sale (PS) ratio of 7.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.26%, a ROC of -73.05% and a ROE of -158.25%. The company’s profit margin is -57.26%, its EBITDA margin is -51.60%, and its revenue ttm is $95.24 Million , which makes it $1.70 revenue per share.

Of the last four earnings reports from Evolus Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Evolus Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.43), with a target price of $16.57, which is +85.14% compared to the current price. The earnings rating for Evolus Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evolus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.39, ATR14 : 1.07, CCI20 : -144.02, Chaikin Money Flow : -0.19, MACD : -0.69, Money Flow Index : 39.32, ROC : -29.37, RSI : 20.00, STOCH (14,3) : 9.98, STOCH RSI : 0.31, UO : 35.70, Williams %R : -90.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Crystal Muilenburg (Sold 11 857 shares of value $123 110 ), David Moatazedi (Sold 211 605 shares of value $2 445 178 ), David N. Gill (Sold 10 313 shares of value $137 664 ), Lauren P. Silvernail (Sold 92 689 shares of value $1 130 276 ), Rui Avelar (Sold 24 485 shares of value $258 910 ), Vikram Malik (Sold 93 160 shares of value $971 283 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
6 (85.71 %)
Moderate Buy
1 (14.29 %)
1 (14.29 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (14.29 %)
Summary RatingStrong Buy
1.43
Strong Buy
1.43
Strong Buy
1.57

Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

CEO: David Moatazedi

Telephone: +1 949 284-4555

Address: 520 Newport Center Drive, Newport Beach 92660, CA, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

55%45%

TipRanks News for EOLS

Tue, 02 Aug 2022 13:05 GMT Mizuho Securities Believes Evolus (EOLS) Still Has Room to Grow

- TipRanks. All rights reserved.

Wed, 11 May 2022 02:25 GMT Evolus (EOLS) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Wed, 09 Mar 2022 07:29 GMT Evolus Updates 1 Key Risk Factor

- TipRanks. All rights reserved.

Tue, 08 Feb 2022 09:18 GMT Evolus (EOLS) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits